Ivan Netuka

Featured in: Favicon

jamanetwork.com Favicon

onlinecjc.ca Favicon

emjreviews.com Favicon

internationaljournalofcardiology.com Favicon

Articles

Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial | Cardiology | JAMA Cardiology | JAMA Network

Jan 10, 2025 | jamanetwork.com | Ivan Netuka |Jason Katz |Francis D. Pagani

Key PointsQuestion Do common conditions (prior percutaneous coronary intervention [PCI], coronary artery bypass grafting [CABG], stroke, or peripheral vascular disease [PVD]) for which aspirin is indicated influence outcomes differentially when aspirin is eliminated from the antithrombotic regimen in recipients of the Heartmate 3 (HM3 [Abbott Cardiovascular]) left ventricular assist device (LVAD)?
Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial

Nov 11, 2023 | jamanetwork.com | Mandeep R. Mehra |Ivan Netuka |Columbia College |Jason Katz

Key PointsQuestion Can aspirin be safely avoided as part of an antithrombotic regimen including a vitamin K antagonist with a fully magnetically levitated left ventricular assist device (LVAD), and can such an approach reduce residual risk of nonsurgical bleeding complications?

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →